Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus

Jean M Whaley,1 Mark Tirmenstein,2 Timothy P Reilly,2 Simon M Poucher,3 JoAnne Saye,4 Shamik Parikh,5 James F List61Bristol-Myers Squibb, Metabolic Disease Discovery Biology, Research and Development, Princeton, NJ, USA; 2Bristol-Myers Squibb, Drug Safety Evaluation, Research and Development, New Br...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Whaley JM, Tirmenstein M, Reilly TP, Poucher SM, Saye J, Parikh S, List JF
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Specialties of internal medicine
RC581-951
Acceso en línea:https://doaj.org/article/a003cb7fbb89442891cbacb323aff1ba
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares